News

Video

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MD,Alexey V. Danilov, MD, PhD

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
1 expert in this video
Related Content
Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL